CALR and essential thrombocythemia: A JAK2V617F driver mutation can be found in about 60% of ET cases, calreticulin (CALR), and MPL mutations in about 20% and 3%, while only a small subgroup of patients presents without one of these driver mutations (so-called “wild-type”) [21, 30].